Healthcare >> CEO Interviews >> May 7, 2001
DR. MICHAEL CONRAD, PhD (President, CEO, Chairman) is responsible for
the development of Chromagen's proprietary fluorescent technologies. Dr.
Conrad received a PhD in Physiological Chemistry from Stanford
University and has contributed numerous scientific advances over a 21
year career which has included both academic and industry positions. Dr.
Conrad is a former research faculty member, American Heart Association
Scholar, and American Cancer Society Fellow at the University of
California, San Diego. Profile
TWST: Could you begin by giving us a brief overview of Chromagen?Mr. Conrad: Biotechnology companies focused on products for human health
can be easily grouped based on market focus: 1)